Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

252 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-12-31

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vitamin C supplementation (500 mg per day) given to pregnant women who can not quit smoking will improve the pulmonary function tests in their offspring measured at 3 months of age.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP) Longer Term Follow Up

NCT06106646

Asthma Pulmonary Function Wheezing +1 more

RECRUITING

VCSIP Follow-up Study

NCT03203603

Asthma Pulmonary Function Wheezing +1 more

COMPLETED

Vitamin A for BPD Prevention

NCT04563429

The Relationship Between Oral Vitamin A Administration and the Incidence of BPD in Preterm Infants Born Before Week 29 of Pregnancy

UNKNOWN NA

Vitamin A Supplementation in Preterm Infants

NCT00063596

Infant, Premature

UNKNOWN NA

Effects of Increased Maternal Choline Intake on Child Cognitive Development

NCT04987099

Pregnancy

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Smoking during pregnancy remains a major public health problem as at least 12% of pregnant women cannot quit smoking during pregnancy. This addiction is the largest preventable cause of childhood respiratory illness, including asthma, and children whose mothers smoked during pregnancy show lifetime decreases in pulmonary function. Smoking is a unique morbidity in that it is addictive, heavily advertised and recent genome studies show there are genotypes that significantly increase the likelihood of being unable to quit. Teen pregnancy, low income, low education, and living with another smoker are important factors increasing the odds of smoking during pregnancy. Pulmonary function tests done shortly after birth in babies born to mothers who smoked during pregnancy show decreased pulmonary function as measured by decreased respiratory flows and respiratory compliance and altered tidal breathing patterns. These changes can still be measured even after the infants have reached adulthood. Multiple epidemiologic studies show that these decreases in pulmonary function lead to increased respiratory disease and costs of hundreds of millions of dollars per year.

The primary aim of this double-blind, placebo controlled, randomized, multi-site study is to demonstrate improved pulmonary function testing at 3 months of age, in infants delivered to smoking mothers who are randomized to 500 mg/day of supplemental vitamin C versus placebo at less than or equal to 22 weeks of pregnancy. We will recruit 278 smoking pregnant women into the study. Patients will meet with research personnel at each prenatal visit and smoking cessation will be actively encouraged. Patients will be monitored with a set of serial biomarkers to assess smoking and medication compliance, including urine cotinine levels, smoking questionnaires, pill counts and fasting plasma ascorbic acid levels. Pulmonary function tests will be done at 3 months of age and will measure forced expiratory flows. The infants will also be followed through one year of age with monthly validated respiratory questionnaires and a follow-up pulmonary function test at 12 months of age. Success of this study is supported by strong pilot data showing statistically significant improvements at about 48 hours of age in pulmonary function tests in infants born to smoking mothers who received vitamin C versus placebo, and preliminary data showing a lower incidence of wheezing at 12 months of age in these infants. Key genetic polymorphisms shown to increase sensitivity to in-utero smoke exposure will also be measured. The success of this study is also supported by animal models showing the effectiveness of vitamin C to preserve pulmonary function and genetic and epidemiologic studies linking the effects of smoking during pregnancy to oxidant mechanisms. The secondary aims of the study include: 1) to demonstrate a decreased incidence of wheezing through 12 months of age in infants delivered to smoking mothers who are randomized to 500mg/day of supplemental vitamin C versus placebo during pregnancy; 2) to demonstrate improved pulmonary function tests at 12 months of age in these infants.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Function; Newborn, Abnormal Infant Wheeze In-utero Nicotine Second Hand Smoke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

placebo tablet+prenatal vitamin

A daily placebo tablet

Group Type PLACEBO_COMPARATOR

Placebo tablet+prenatal vitamin

Intervention Type DIETARY_SUPPLEMENT

Vitamin C +prenatal vitamin

500 mg vitamin C /day

Group Type ACTIVE_COMPARATOR

Vitamin C +prenatal vitamin

Intervention Type DIETARY_SUPPLEMENT

Pregnant smoking women will be randomized to daily vitamin C (500 mg) versus daily placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin C +prenatal vitamin

Pregnant smoking women will be randomized to daily vitamin C (500 mg) versus daily placebo

Intervention Type DIETARY_SUPPLEMENT

Placebo tablet+prenatal vitamin

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ascorbic acid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Singleton gestation
* ≥ 15 years old
* Gestational age between 13 and 22 weeks
* Receiving prenatal care
* Current smoker
* English speaking

Exclusion Criteria

* Gestational age ≥ 23 and 0/7 weeks
* Multiple gestation
* Major fetal congenital anomalies
* Current use of illicit drugs
* Current alcohol abuse
* Use of vitamin C (≥ 500 mg/day)\>3 days per week since last menstrual period
* Refusal to abstain from vitamin or supplements containing significant vitamin C other than those provided through or approved by study staff
* History of kidney stone in patient
* Insulin dependent diabetes
* Complex maternal medical conditions
* Participation in other conflicting research projects
* Unable to demonstrate stable method of communication
* Pregnancy by in-vitro fertilization
* Plan to terminate pregnancy
* Failure of medication compliance trial
* Failure to return in designated period during placebo run-in
* Body mass index \> 50 at screening

Minimum Eligible Age

15 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes